AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Alnylam Pharmaceuticals Announces Board Changes, Appoints Stuart Arbuckle as New Director
ByAinvest
Wednesday, Dec 3, 2025 8:04 am ET1min read
Alnylam Pharmaceuticals announced the departure of Mike Bonney and Carolyn Bertozzi from its Board of Directors, and the appointment of Stuart Arbuckle as a new independent director. Bonney served as Board Chair from 2015 to 2021 and as Executive Chair from 2021 to 2023, while Bertozzi joined the Board in 2023 and served on the Nominating and Corporate and Science and Technology Committees. Arbuckle brings extensive experience in biopharmaceutical commercialization and leadership from companies such as GSK, Amgen, and Vertex.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet